中国医药追讨9800万业绩补偿！

Core Viewpoint - China National Pharmaceutical Group (中国医药) has achieved a preliminary legal victory in a contract dispute regarding performance compensation, with a court ruling in favor of the company to recover nearly 98 million yuan from Tibet Tiansheng Taifeng Pharmaceutical Co., Ltd. [3][4] Group 1: Legal Proceedings - The Beijing Second Intermediate People's Court has ruled that Tibet Tiansheng must pay China National Pharmaceutical 98.07 million yuan in performance compensation and interest, with Xu Panfeng bearing joint liability for the debt [6]. - The lawsuit originated in October 2024, initiated by China National Pharmaceutical against Tibet Tiansheng and Xu Panfeng due to unmet performance compensation obligations [4][5]. - The total amount involved in the case is approximately 139 million yuan, which could significantly impact the financial status of China National Pharmaceutical [6]. Group 2: Financial Implications - The performance compensation of nearly 98 million yuan represents about one-third of China National Pharmaceutical's net profit of 29.4 million yuan for the first half of 2025, highlighting its importance for the company's annual performance [6]. - The company reported a revenue of 17.076 billion yuan for the first half of 2025, reflecting a year-on-year decline of 6.71% [6]. Group 3: Future Considerations - There is uncertainty regarding whether Tibet Tiansheng will appeal the court's decision, as the company has not yet provided a response [6].